Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients (EtECAR-HD)
Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial
Sponsor: Amgen
Listed as NCT03182699, this PHASE4 trial focuses on Chronic Kidney Disease Requiring Chronic Dialysis and Left Ventricular Hypertrophy and remains completed. Sponsored by Amgen, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2020 — Jul 2020 [monthly]
Completed PHASE4
▶ Show 7 earlier versions
-
May 2020 — Jun 2020 [monthly]
Completed PHASE4
-
Apr 2020 — May 2020 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Aug 2019 — Apr 2020 [monthly]
Recruiting PHASE4
Status: Active Not Recruiting → Recruiting
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Rainer Oberbauer
For direct contact, visit the study record on ClinicalTrials.gov .